- Home
- BLTE vs NVAX Comparison
BLTE vs NVAX Comparison
Compare BLTE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- NVAX
- Stock Information
- Founded
- BLTE 2018
- NVAX 1987
- Country
- BLTE United States
- NVAX United States
- Employees
- BLTE N/A
- NVAX N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLTE Health Care
- NVAX Health Care
- Exchange
- BLTE Nasdaq
- NVAX Nasdaq
- Market Cap
- BLTE 1.7B
- NVAX 2.0B
- IPO Year
- BLTE 2022
- NVAX 1995
- Fundamental
- Price
- BLTE $57.60
- NVAX $10.14
- Analyst Decision
- BLTE Strong Buy
- NVAX Buy
- Analyst Count
- BLTE 4
- NVAX 6
- Target Price
- BLTE $59.00
- NVAX $17.83
- AVG Volume (30 Days)
- BLTE 40.3K
- NVAX 7.9M
- Earning Date
- BLTE 11-12-2024
- NVAX 11-07-2024
- Dividend Yield
- BLTE N/A
- NVAX N/A
- EPS Growth
- BLTE N/A
- NVAX N/A
- EPS
- BLTE N/A
- NVAX N/A
- Revenue
- BLTE N/A
- NVAX $987,667,000.00
- Revenue This Year
- BLTE N/A
- NVAX N/A
- Revenue Next Year
- BLTE N/A
- NVAX N/A
- P/E Ratio
- BLTE N/A
- NVAX N/A
- Revenue Growth
- BLTE N/A
- NVAX N/A
- 52 Week Low
- BLTE $31.01
- NVAX $3.53
- 52 Week High
- BLTE $57.82
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- BLTE 83.16
- NVAX 35.03
- Support Level
- BLTE $55.63
- NVAX $9.62
- Resistance Level
- BLTE $56.37
- NVAX $10.80
- Average True Range (ATR)
- BLTE 1.65
- NVAX 0.97
- MACD
- BLTE 0.53
- NVAX -0.37
- Stochastic Oscillator
- BLTE 97.94
- NVAX 9.29
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.